L-093-2005
Agreement ID
L-093-2005
Lead IC
NIAID
Exclusivity
Exclusive
External Party
Janssen Vaccines & Prevention B.V.
Fiscal Year
2022
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-2000 Recombinant Vaccines Based on Poxvirus Vectors
TAB-562 Vaccination Strategies to Provide Protection Against the Ebola Virus
TAB-1003 Accelerated Vaccination Strategies to Provide Protection Against Viral Infections
TAB-4863 Development of a Prime-Boost Vaccine Strategy for Comprehensive Protection Against Filovirus Infections
TAB-4889 Innovative Vaccine Technology Advancing Comprehensive Immunity Against Filoviruses
TAB-562 Vaccination Strategies to Provide Protection Against the Ebola Virus
TAB-1003 Accelerated Vaccination Strategies to Provide Protection Against Viral Infections
TAB-4863 Development of a Prime-Boost Vaccine Strategy for Comprehensive Protection Against Filovirus Infections
TAB-4889 Innovative Vaccine Technology Advancing Comprehensive Immunity Against Filoviruses